# DESTINY-Lung02

Source: https://onco.cc/trials/destiny-lung02/  
OnCo record `destiny-lung02` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DESTINY-Lung02 confirmed that the antibody-drug conjugate trastuzumab deruxtecan shrinks about half of HER2-mutant lung cancers after chemotherapy and that the lower dose works as well with less lung inflammation.

## Summary

DESTINY-Lung02 randomised 152 patients with metastatic HER2-mutant non-small-cell lung cancer that had progressed after platinum chemotherapy to trastuzumab deruxtecan at 5.4 mg/kg or 6.4 mg/kg every three weeks. DESTINY-Lung01 had shown a 55 percent response rate at 6.4 mg/kg but with interstitial lung disease in a quarter of patients.

The confirmed response rate was 49.0 percent at 5.4 mg/kg (102 patients) and 56.0 percent at 6.4 mg/kg (50 patients), with median durations of response of 16.8 and 5.9 months. Drug-related interstitial lung disease occurred in 12.9 percent at the lower dose and 28.0 percent at the higher dose.

The FDA had granted accelerated approval in August 2022 on the interim data, the first HER2-directed therapy for lung cancer, at the 5.4 mg/kg dose; DESTINY-Lung04 is testing the drug first line against chemotherapy plus pembrolizumab.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Registry id: NCT04644237
- Phase: 2
- Setting: Previously treated metastatic HER2 (ERBB2)-mutant non-small-cell lung cancer: trastuzumab deruxtecan 5.4 mg/kg versus 6.4 mg/kg
- Sponsor: Daiichi Sankyo / AstraZeneca
- Enrolled: 152
- Result: Confirmed response rate 49.0% (5.4 mg/kg) vs 56.0% (6.4 mg/kg); interstitial lung disease 12.9% vs 28.0%.
- Outcomes: Confirmed objective response rate: Trastuzumab deruxtecan 5.4 mg/kg 49% vs Trastuzumab deruxtecan 6.4 mg/kg 56%
- Replication: DESTINY-Lung01 (response rate 55 percent at 6.4 mg/kg) preceded it; Beamion LUNG-1 (zongertinib) later showed a 71 percent response with an oral inhibitor in the same population.

## Sources

- ClinicalTrials.gov NCT04644237: https://clinicaltrials.gov/study/NCT04644237
- Journal of Clinical Oncology 2023: https://doi.org/10.1200/JCO.23.01361

## Connected records

- cancers: [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)
- terms: [Interstitial lung disease (ILD) / pneumonitis](https://onco.cc/terms/ild/)

---
JSON: https://onco.cc/api/v1/entities/destiny-lung02.json